Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.

Sustainability claims are growing as targets of reviews by BBB National Programs investigative divisions, which also anticipate more ad violations from online dark patterns in 2022.

BBB National Programs’ appeals panel agrees with National Advertising Division that PLx should modify TV ad to clearly and conspicuously disclose that “clinically shown to cause fewer ulcers than plain aspirin” refers to Vazalore 325 mg and not 81-mg dose.

Over  past year, PLx's Vazalore ad claimswere reviewed National Advertising Division before and after launch. As PLx appeals NAD’s post-launch review findings, NAD attorneys send questions about pre-launch claims to FTC.